CSIMarket
 
Windtree Therapeutics Inc  (WINT)
Other Ticker:  
 
 
Price: $0.3537 $-0.01 -1.723%
Day's High: $0.3599 Week Perf: -0.25 %
Day's Low: $ 0.35 30 Day Perf: 7.84 %
Volume (M): 38 52 Wk High: $ 18.48
Volume (M$): $ 14 52 Wk Avg: $1.28
Open: $0.36 52 Wk Low: $0.28



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 5
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -25
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Windtree Therapeutics Inc
Windtree Therapeutics Inc. is a biotechnology company that focuses on developing novel therapeutics for respiratory diseases. The company is primarily known for its proprietary technology platform called KL4 surfactant, which is a synthetic formulation designed to mimic the natural surfactant found in healthy lungs. This platform is utilized in the development of various inhalation therapies for diseases such as respiratory distress syndrome (RDS) in premature infants and chronic obstructive pulmonary disease (COPD) in adults. The aim of Windtree Therapeutics is to improve the quality of life for patients suffering from respiratory conditions by providing effective and safe treatment options.


   Company Address: 2600 Kelly Road, Suite 100 Warrington 18976 PA
   Company Phone Number: 488-9300   Stock Exchange / Ticker: NASDAQ WINT
   WINT is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Windtree Renews Collaboration with Chang Gung University to Advance SERCA2a Research in Cardiovascular Therapies

Published Thu, Feb 1 2024 1:00 PM UTC

WARRINGTON, Pa., Feb. 01, 2024 - Windtree Therapeutics, a prominent biotechnology company focusing on late-stage interventions for critical cardiovascular disorders, has recently announced the renewal of its partnership with Chang Gung University in Taiwan. This collaboration aims to further scientific research on SERCA2a, an essential target in Windtree's cardiovascular por...

Stock Market Announcement

Windtree Therapeutics Partners with Ladenburg Thalmann & Co. to Unlock Stockholder Value and Eliminate Million-Dollar Liability

Published Wed, Jan 31 2024 1:00 PM UTC

Ladenburg Thalmann & Co. Engaged to Assess Strategic Alternatives for Windtree Therapeutics Inc., Maximizing Stockholder Value
WARRINGTON, Pa., Jan. 31, 2024 - Windtree Therapeutics, Inc. (Windtree or the Company) (NasdaqCM: WINT), a leading biotechnology company specializing in late-stage interventions for critical cardiovascular disorders, has announced its engagement ...

Shares

Windtree Successfully Eliminates $15 Million Contingent Liability to Deerfield Management Company

Published Thu, Jan 25 2024 1:30 PM UTC



In a recent press release, Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced a significant development in its efforts to advance interventions for critical cardiovascular disorders. The biotechnology company revealed that it has entered into an Exchange and Termination Agreement with affiliates of Deerfield Management Company, effectively eliminating a $15 mil...

Licensing Agreement

Windtree Therapeutics Expands Presence in Asia-Pacific through Licensing Agreement with Lees Pharmaceuticals

Published Wed, Jan 17 2024 1:00 PM UTC

In an exciting development, Windtree Therapeutics, a biopharmaceutical company specializing in the development of innovative therapeutics for cardiovascular and respiratory diseases, has announced a strategic license agreement with Lees Pharmaceuticals. This collaboration aims to develop and commercialize two groundbreaking product candidates, Istaroxime and Rostafuroxin, in...

Clinical Study

Unveiling Istaroxime: A Pure SERCA2a Activator with Game-Changing Potential in Arrhythmia Treatment

Published Tue, Jan 2 2024 9:05 PM UTC

In recent years, there have been significant advancements in the field of cardiovascular medicine, particularly in the treatment of arrhythmias. Windtree Therapeutics, a leading biotechnology company, has announced impressive findings from a new preclinical study involving istaroxime, a pure SERCA2a activator. These findings further strengthen the previously reported clinica...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com